早期子宫内膜癌的腹腔镜单孔手术与传统腹腔镜手术对比:一项随机对照非劣效性试验
这项随机对照非劣效性试验将临床IA、IB期、1-3级子宫内膜癌患者随机分配至腹腔镜单孔手术(LESS)组(n=53)或传统腹腔镜手术(CLS)组(n=54),评估手术时间和盆腔淋巴结清扫数。结果显示LESS组平均少清扫4.6枚盆腔淋巴结,在非劣效界值内;两组总手术时间相当,术中及术后并发症发生率、估计出血量和术后住院时间无显著差异;中位随访34个月(范围2-242),两组无进展生存率和总生存率无显著差异。结论认为LESS手术分期不劣于CLS,可行性、安全性和有效性可接受。
要点
- LESS组平均少清扫4.6枚盆腔淋巴结,在预设非劣效界值(5.2枚)内。
- 两组总手术时间相当,并发症发生率、估计出血量和术后住院时间无显著差异。
- 中位随访34个月(范围2-242),两组无进展生存率和总生存率无显著差异。
核心结论
- LESS手术分期不劣于CLS,对早期子宫内膜癌的手术管理具有可接受的可行性、安全性和有效性。
研究设计与样本
- 随机对照非劣效性试验,纳入临床IA、IB期、1-3级子宫内膜癌患者,随机分配至LESS组(n=53)或CLS组(n=54)。
- 主要终点为手术时间和切除盆腔淋巴结数的非劣效性,手术时间非劣效界值为15%(24分钟),盆腔淋巴结数非劣效界值为20%(5.2枚)。
- 试验注册号:Clinicaltrial.gov NCT01679522。
主要发现
- LESS组(n=53)与CLS组(n=54)在年龄、体重、体重指数、产次、绝经状态、腹部手术史和术前CA-125水平方面无显著差异。
- 两组总手术时间相当。
- LESS组平均少清扫4.6枚盆腔淋巴结,在非劣效界值内。
- 两组术中及术后并发症发生率、估计出血量和术后住院时间无显著差异。
- 中位随访34个月(范围2-242),LESS组与CLS组无进展生存率分别为96.2%和98.1%(P=0.55),总生存率分别为98.1%和100.0%(P=0.31)。
关键数值与推荐
- 手术时间非劣效界值为15%(24分钟)。
- 切除盆腔淋巴结数非劣效界值为20%(5.2枚)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the feasibility and safety of laparo-endoscopic single-site surgery (LESS) compared with conventional laparoscopic surgery (CLS) for early-stage endometrial cancer. METHODS: Patients with clinical stage IA, IB, grade 1-3 endometrial cancer were randomly assigned to undergo LESS or CLS. The primary endpoint was the non-inferiority of LESS to CLS in terms of operation time and the number of resected pelvic lymph nodes. We set the non-inferior margin of the operation time as within 15% (24 min) and the number of resected pelvic lymph nodes as within 20% (5.2 lymph nodes). RESULTS: There was no significant difference between the LESS group (n = 53) and the CLS group (n = 54) in terms of age, weight, body mass index, parity, menopausal status, history of abdominal surgery, and preoperative CA-125 levels. The total operation time was comparable between the two groups. On average, 4.6 fewer pelvic lymph nodes were retrieved in the LESS group, which was within the non-inferiority margin. There were no significant differences in the incidence of intra- and postoperative complications, estimated blood loss, and postoperative hospital stay between the two groups. After a median follow-up time of 34 months (range, 2-242), the progression-free survival rates were 96.2% and 98.1% (P = 0.55) in the LESS group and the CLS group, and the overall survival rates were 98.1% and 100.0% (P = 0.31), respectively. CONCLUSION: LESS surgical staging was non-inferior to CLS and had acceptable feasibility, safety, and efficacy for the surgical management of early-stage endometrial cancer. TRIAL REGISTRATION: Clinicaltrial.gov identifier number: NCT01679522.
引用
- Kang OJ, Nam JH, Park JY, et al. Laparo-endoscopic single-site versus conventional laparoscopic surgery for early-stage endometrial cancer: A randomized controlled non-inferiority trial. Gynecol Oncol. 2023. PMID: 37105060. doi:10.1016/j.ygyno.2023.04.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。